UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,335	07/21/2006	Merritt B. Andrus	49506-12	9418
	7590 12/16/200 ER GILSON & LIONE	EXAMINER		
UTAH OFFICE			NWAONICHA, CHUKWUMA O	
405 South Main Street Suite 800		ART UNIT	PAPER NUMBER	
SALT LAKE CITY, UT 84111-3400			1621	
			MAIL DATE	DELIVERY MODE
			12/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/597,335	ANDRUS ET AL.			
Office Action Summary	Examiner	Art Unit			
	CHUKWUMA O. NWAONICHA	1621			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim 11 apply and will expire SIX (6) MONTHS from 12 cause the application to become ABANDONEI	I.  nely filed  the mailing date of this communication.  D (35 U.S.C. § 133).			
Status					
1) ☐ Responsive to communication(s) filed on 13 Oct 2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This 3) ☐ Since this application is in condition for allowant closed in accordance with the practice under Expression in the practice of the condition of the condition is in condition for allowant closed in accordance with the practice under Expression in the condition is in the condition of the condition of the condition is in the condition of the condition in the condition is in the condition of the condition of the condition is in the condition of the co	action is non-final. ice except for formal matters, pro				
Disposition of Claims					
4) Claim(s) 69-87 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 69-87 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or  Application Papers	vn from consideration.				
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the objected to by the Examiner Replacement drawing sheet(s) including the correction.  11) The oath or declaration is objected to by the Examiner	epted or b) $\square$ objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)  1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 06/02/2008 See next page.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Page No(s)/Mail Date 01/18/2008, 07/06/2007, 02/26/2007 & 11/17/2006

Application/Control Number: 10/597,335 Page 2

Art Unit: 1621

#### **DETAILED ACTION**

#### **Current Status**

- 1. Claims 69-87 are pending in the application.
- 2. This action is responsive to Applicants' amendment of 13 October 2007.
- 3. Receipt and entry of Applicants' amendment is acknowledged.

#### Election/Restrictions have been vacated following Applicants amendments.

#### **Priority**

Applicants' claim for domestic priority under 35 U.S.C. 119(e) is acknowledged.

#### Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 69, 73, 75 and 76 are rejected under 35 U.S.C. 103(a) as being unpatentable over Engler et al., {Lewis Acid-Promoted Reactions of Unsymmetrically Substituted

Application/Control Number: 10/597,335

Art Unit: 1621

Stilbenes with 2-Methoxy-1,4-benzoquinones: Stereoselective Synthesis of trans-2,3-Diaryl-2,3-dihydrobenzofurans, Journal of Organic Chemistry (1995), 60(12), 3700-3706} and Gokaraju et al., {WO 2004000302 same as US 7,026,518}.

Page 3

Applicants claim the compound of the general formula 1; wherein all the variables are as defined in the claims.

$$A_1O$$
 $OA_2$ 
 $OA_3$ 

Formula 1

### Determination of the scope and content of the prior art (M.P.E.P. §2141.01)

Engler et al. teach the compound of the formula 2, and its pharmaceutically acceptable salt. See abstract.

Formula 2

Gokaraju et al. teach applicants claimed compound as shown; wherein R1-R3 are methyl and aceto groups. See page 5, lines 1-4 of WO 2004000302.

Art Unit: 1621

$$\mathbb{R}^{1}$$
O $\mathbb{R}^{2}$ 

Formula 2

# Ascertainment of the difference between the prior art and the claims (M.P.E.P.. §2141.02)

Applicants claimed compound of the general formula 1 differs from the teaching of the prior art references in that the instantly claimed compound of the general formula 1 is a homolog of the prior art's compound. That while Applicants claim hydrogen, the prior art references teach methyl group.

# <u>Finding of prima facie obviousness--rational and motivation (M.P.E.P.. §2142-2143)</u>

The instantly claimed compounds of the general formula 1 would have been obvious to one of ordinary skill in view of the compounds of Engler et al. and Gokaraju et al. because the instant compound is a homolog of the compound taught by the references. In the instantly claimed application, Applicants claim a compound wherein the phenyl ring is substituted with OH while the prior art of Engler et al. and Gokaraju et al. teach compounds wherein the phenyl ring is substituted with OCH<sub>3</sub>. Hydrogen versus methyl group is obvious because of their property relationship. In re Henze, 85 U.S.P.Q. 261, 263 (C.C.P.A. 1950). To be patentable, novel members of homologous series of chemical compounds must possess unobvious or unexpected beneficial

properties not possessed by homologous compound disclosed in prior art In re Hass, 141 F.2d 127, 60 USPQ 548 (CCPA 1944). Therefore, the prior art's compound would be expected to have similar properties and activities as the compounds of the present invention.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 69, 72, 75 and 76 are rejected under 35 U.S.C. 102(e) as being anticipated by Lockwood et al., {US 7,145,025 or WO 2004011423}.

Lockwood et al. disclose applicants claimed compound as shown below. See Abstract of WO 2004011423.

Art Unit: 1621

Claims 69-72 and 75-78 are rejected under 35 U.S.C. 102(a) as being anticipated by Scaramuzzino, {EP 1336602}

Scaramuzzino discloses applicants claimed compound as shown below. See Abstract.

CO2H سر

HO E 
$$(CH_2)_3$$
  $C$   $NO_2$ 

Art Unit: 1621

Claims 69, 70, 73 and 74-84 are rejected under 35 U.S.C. 102(b) as being anticipated by Nicolosi et al., {Chemo-enzymatic preparation of resveratrol derivatives, Journal of Molecular Catalysis B: Enzymatic (2002), 16(5-6), 223-229}.

Nicolosi et al. disclose Applicants claimed compound as shown below. See page 228.

Claims 69-87 are rejected under 35 U.S.C. 102(b) as being anticipated by Gokaraju et al., {WO 2004000302 same as US 7,026,518}.

Application/Control Number: 10/597,335 Page 8

Art Unit: 1621

Gokaraju et al. disclose applicants claimed compound as shown in the abstract. See page 5, line 5 of WO 2004000302.

The examiner is respectfully requesting that applicants provide the chemical structure for each species of claim 76. This submission would make the record clearer and advance the prosecution of this application.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chukwuma O. Nwaonicha whose telephone number is 571-272-2908. The examiner can normally be reached on Monday thru Friday, 8:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Daniel Sullivan can be reached on 571-272-0779. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Center (EBC) at 866-217-9197 (toll-free).

/Chukwuma O. Nwaonicha/ Examiner, Art Unit 1621 Application/Control Number: 10/597,335 Page 9

Art Unit: 1621

/Karl J. Puttlitz/ Primary Examiner, Art Unit 1621